Posted by Michael Wonder on 02 May 2022
Prices of Tecentriq, Avastin go down due to broader insurance benefits
2 May 2022 - The Government granted health insurance benefits to the combination therapy of Tecentriq and Avastin to treat hepatocellular carcinoma and Tecentriq monotherapy to treat non-small-cell lung cancer, effective from May.
The Government also lowered the maximum rates of reimbursement on each drug.
